Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 5, 2016, primarily to furnish a press release detailing its financial and operating results for the first quarter ended March 31, 2016. While the 8-K itself does not contain the detailed financial figures, it directs investors to the attached press release (Exhibit 99.1) for this crucial information. Investors should review this press release to understand the company's performance, including revenue, profitability, and key operational metrics for the period. The filing serves as a formal notification of the release of quarterly results. The information contained in the press release, while significant for understanding REGN's current business performance and future outlook, is specifically noted as not being "filed" for purposes of Section 18 of the Securities Exchange Act, meaning it does not carry the same legal implications as formally filed documents unless expressly incorporated into another filing.
Key Highlights
- 1REGN filed an 8-K on May 5, 2016, to report Q1 2016 financial and operating results.
- 2The key financial details are contained within a press release furnished as Exhibit 99.1.
- 3Investors need to consult Exhibit 99.1 for specific performance data.
- 4The filing covers the quarter ended March 31, 2016.
- 5Information furnished in this 8-K is not deemed "filed" under Section 18 of the Exchange Act unless explicitly incorporated by reference.